The Vitality Peptide
Bremelanotide (Melanocortin receptor agonist)
PT-141 (Bremelanotide) is a melanocortin receptor agonist that enhances sexual function through central nervous system mechanisms. It is the first FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women, marketed as Vyleesi. Unlike PDE5 inhibitors (Viagra, Cialis), PT-141 works on desire and arousal through brain pathways, not peripheral blood flow.
PT-141 activates melanocortin-4 receptors (MC4R) in the brain, which are involved in sexual arousal and desire pathways. This central mechanism distinguishes it from all other sexual health treatments, which work peripherally.
Binds to and activates melanocortin-4 receptors (MC4R) in the hypothalamus, stimulating neural pathways associated with sexual desire and arousal.
Increases dopaminergic activity in reward centers of the brain, enhancing motivation and pleasure associated with sexual activity.
Works through the CNS rather than peripheral vasculature, addressing desire (the psychological component) rather than just physical function.
Effective in both men and women, as the melanocortin system is a shared pathway for sexual motivation across sexes.
FDA-approved for hypoactive sexual desire disorder in women, with clinical evidence for improved sexual desire and arousal in both sexes.
Works through brain pathways rather than blood flow, making it effective for desire-based sexual health issues that PDE5 inhibitors cannot address.
Clinical evidence supports efficacy in both men and women, unlike most sexual health treatments which are sex-specific.
For men who don't respond to PDE5 inhibitors or have desire-based issues, PT-141 offers a mechanistically different approach.
PT-141 (Bremelanotide) received FDA approval in 2019 as Vyleesi for treatment of hypoactive sexual desire disorder in premenopausal women, the first centrally-acting sexual health treatment approved.
Phase III clinical trials (RECONNECT studies) demonstrated significant improvement in sexual desire and reduction in distress related to low sexual desire in women treated with Bremelanotide.
In clinical studies of men with erectile dysfunction, PT-141 produced erections in 68% of subjects who had not responded to PDE5 inhibitors, demonstrating its unique mechanism of action.
PT-141 has undergone extensive Phase III clinical trials and received FDA approval (as Vyleesi), providing robust safety data. The most common side effect is nausea. It is contraindicated in patients with uncontrolled hypertension.
Research Status
PT-141 (Bremelanotide) has the highest level of clinical evidence in this library, having completed Phase III clinical trials and received FDA approval as Vyleesi in 2019. Post-marketing surveillance data continues to confirm its safety and efficacy profile.
Regulatory Note
FDA-approved as Vyleesi (bremelanotide injection) for hypoactive sexual desire disorder in premenopausal women. Available by prescription. Off-label use for men and other indications occurs through physician practices and compounding pharmacies.